MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene

Jisun Kim, Felipe C. Geyer, Luciano G. Martelotto, Charlotte Ky Ng, Raymond S. Lim, Pier Selenica, Anqi Li, Fresia Pareja, Nicola Fusco, Marcia Edelweiss, Rahul Kumar, Rodrigo Gularte-Merida, Andre N. Forbes, Ekta Khurana, Odette Mariani, Sunil Badve, Anne Vincent-Salomon, Larry Norton, Jorge S. Reis-Filho, Britta Weigelt

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Breast adenoid cystic carcinoma (AdCC), a rare type of triple-negative breast cancer, has been shown to be driven by MYB pathway activation, most often underpinned by the MYB-NFIB fusion gene. Alternative genetic mechanisms, such as MYBL1 rearrangements, have been reported in MYB-NFIB-negative salivary gland AdCCs. Here we report on the molecular characterization by massively parallel sequencing of four breast AdCCs lacking the MYB-NFIB fusion gene. In two cases, we identified MYBL1 rearrangements (MYBL1-ACTN1 and MYBL1-NFIB), which were associated with MYBL1 overexpression. A third AdCC harboured a high-level MYB amplification, which resulted in MYB overexpression at the mRNA and protein levels. RNA-sequencing and whole-genome sequencing revealed no definite alternative driver in the fourth AdCC studied, despite high levels of MYB expression and the activation of pathways similar to those activated in MYB-NFIB-positive AdCCs. In this case, a deletion encompassing the last intron and part of exon 15 of MYB, including the binding site of ERG-1, a transcription factor that may downregulate MYB, and the exon 15 splice site, was detected. In conclusion, we demonstrate that MYBL1 rearrangements and MYB amplification probably constitute alternative genetic drivers of breast AdCCs, functioning through MYBL1 or MYB overexpression. These observations emphasize that breast AdCCs probably constitute a convergent phenotype, whereby activation of MYB and MYBL1 and their downstream targets can be driven by the MYB-NFIB fusion gene, MYBL1 rearrangements, MYB amplification, or other yet to be identified mechanisms.

Original languageEnglish (US)
JournalJournal of Pathology
DOIs
StateAccepted/In press - Jan 1 2017

Fingerprint

Adenoid Cystic Carcinoma
Gene Fusion
Breast
Exons
Triple Negative Breast Neoplasms
RNA Sequence Analysis
High-Throughput Nucleotide Sequencing
Gene Rearrangement
Salivary Glands
Introns
Transcription Factors
Down-Regulation
Binding Sites
Genome
Phenotype
Messenger RNA
Proteins

Keywords

  • Adenoid cystic carcinoma
  • Breast
  • MYB
  • MYB-NFIB fusion gene
  • MYBL1

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Kim, J., Geyer, F. C., Martelotto, L. G., Ng, C. K., Lim, R. S., Selenica, P., ... Weigelt, B. (Accepted/In press). MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene. Journal of Pathology. https://doi.org/10.1002/path.5006

MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene. / Kim, Jisun; Geyer, Felipe C.; Martelotto, Luciano G.; Ng, Charlotte Ky; Lim, Raymond S.; Selenica, Pier; Li, Anqi; Pareja, Fresia; Fusco, Nicola; Edelweiss, Marcia; Kumar, Rahul; Gularte-Merida, Rodrigo; Forbes, Andre N.; Khurana, Ekta; Mariani, Odette; Badve, Sunil; Vincent-Salomon, Anne; Norton, Larry; Reis-Filho, Jorge S.; Weigelt, Britta.

In: Journal of Pathology, 01.01.2017.

Research output: Contribution to journalArticle

Kim, J, Geyer, FC, Martelotto, LG, Ng, CK, Lim, RS, Selenica, P, Li, A, Pareja, F, Fusco, N, Edelweiss, M, Kumar, R, Gularte-Merida, R, Forbes, AN, Khurana, E, Mariani, O, Badve, S, Vincent-Salomon, A, Norton, L, Reis-Filho, JS & Weigelt, B 2017, 'MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene', Journal of Pathology. https://doi.org/10.1002/path.5006
Kim, Jisun ; Geyer, Felipe C. ; Martelotto, Luciano G. ; Ng, Charlotte Ky ; Lim, Raymond S. ; Selenica, Pier ; Li, Anqi ; Pareja, Fresia ; Fusco, Nicola ; Edelweiss, Marcia ; Kumar, Rahul ; Gularte-Merida, Rodrigo ; Forbes, Andre N. ; Khurana, Ekta ; Mariani, Odette ; Badve, Sunil ; Vincent-Salomon, Anne ; Norton, Larry ; Reis-Filho, Jorge S. ; Weigelt, Britta. / MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene. In: Journal of Pathology. 2017.
@article{c309bbbe59d14821bd348ade512153e7,
title = "MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene",
abstract = "Breast adenoid cystic carcinoma (AdCC), a rare type of triple-negative breast cancer, has been shown to be driven by MYB pathway activation, most often underpinned by the MYB-NFIB fusion gene. Alternative genetic mechanisms, such as MYBL1 rearrangements, have been reported in MYB-NFIB-negative salivary gland AdCCs. Here we report on the molecular characterization by massively parallel sequencing of four breast AdCCs lacking the MYB-NFIB fusion gene. In two cases, we identified MYBL1 rearrangements (MYBL1-ACTN1 and MYBL1-NFIB), which were associated with MYBL1 overexpression. A third AdCC harboured a high-level MYB amplification, which resulted in MYB overexpression at the mRNA and protein levels. RNA-sequencing and whole-genome sequencing revealed no definite alternative driver in the fourth AdCC studied, despite high levels of MYB expression and the activation of pathways similar to those activated in MYB-NFIB-positive AdCCs. In this case, a deletion encompassing the last intron and part of exon 15 of MYB, including the binding site of ERG-1, a transcription factor that may downregulate MYB, and the exon 15 splice site, was detected. In conclusion, we demonstrate that MYBL1 rearrangements and MYB amplification probably constitute alternative genetic drivers of breast AdCCs, functioning through MYBL1 or MYB overexpression. These observations emphasize that breast AdCCs probably constitute a convergent phenotype, whereby activation of MYB and MYBL1 and their downstream targets can be driven by the MYB-NFIB fusion gene, MYBL1 rearrangements, MYB amplification, or other yet to be identified mechanisms.",
keywords = "Adenoid cystic carcinoma, Breast, MYB, MYB-NFIB fusion gene, MYBL1",
author = "Jisun Kim and Geyer, {Felipe C.} and Martelotto, {Luciano G.} and Ng, {Charlotte Ky} and Lim, {Raymond S.} and Pier Selenica and Anqi Li and Fresia Pareja and Nicola Fusco and Marcia Edelweiss and Rahul Kumar and Rodrigo Gularte-Merida and Forbes, {Andre N.} and Ekta Khurana and Odette Mariani and Sunil Badve and Anne Vincent-Salomon and Larry Norton and Reis-Filho, {Jorge S.} and Britta Weigelt",
year = "2017",
month = "1",
day = "1",
doi = "10.1002/path.5006",
language = "English (US)",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene

AU - Kim, Jisun

AU - Geyer, Felipe C.

AU - Martelotto, Luciano G.

AU - Ng, Charlotte Ky

AU - Lim, Raymond S.

AU - Selenica, Pier

AU - Li, Anqi

AU - Pareja, Fresia

AU - Fusco, Nicola

AU - Edelweiss, Marcia

AU - Kumar, Rahul

AU - Gularte-Merida, Rodrigo

AU - Forbes, Andre N.

AU - Khurana, Ekta

AU - Mariani, Odette

AU - Badve, Sunil

AU - Vincent-Salomon, Anne

AU - Norton, Larry

AU - Reis-Filho, Jorge S.

AU - Weigelt, Britta

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Breast adenoid cystic carcinoma (AdCC), a rare type of triple-negative breast cancer, has been shown to be driven by MYB pathway activation, most often underpinned by the MYB-NFIB fusion gene. Alternative genetic mechanisms, such as MYBL1 rearrangements, have been reported in MYB-NFIB-negative salivary gland AdCCs. Here we report on the molecular characterization by massively parallel sequencing of four breast AdCCs lacking the MYB-NFIB fusion gene. In two cases, we identified MYBL1 rearrangements (MYBL1-ACTN1 and MYBL1-NFIB), which were associated with MYBL1 overexpression. A third AdCC harboured a high-level MYB amplification, which resulted in MYB overexpression at the mRNA and protein levels. RNA-sequencing and whole-genome sequencing revealed no definite alternative driver in the fourth AdCC studied, despite high levels of MYB expression and the activation of pathways similar to those activated in MYB-NFIB-positive AdCCs. In this case, a deletion encompassing the last intron and part of exon 15 of MYB, including the binding site of ERG-1, a transcription factor that may downregulate MYB, and the exon 15 splice site, was detected. In conclusion, we demonstrate that MYBL1 rearrangements and MYB amplification probably constitute alternative genetic drivers of breast AdCCs, functioning through MYBL1 or MYB overexpression. These observations emphasize that breast AdCCs probably constitute a convergent phenotype, whereby activation of MYB and MYBL1 and their downstream targets can be driven by the MYB-NFIB fusion gene, MYBL1 rearrangements, MYB amplification, or other yet to be identified mechanisms.

AB - Breast adenoid cystic carcinoma (AdCC), a rare type of triple-negative breast cancer, has been shown to be driven by MYB pathway activation, most often underpinned by the MYB-NFIB fusion gene. Alternative genetic mechanisms, such as MYBL1 rearrangements, have been reported in MYB-NFIB-negative salivary gland AdCCs. Here we report on the molecular characterization by massively parallel sequencing of four breast AdCCs lacking the MYB-NFIB fusion gene. In two cases, we identified MYBL1 rearrangements (MYBL1-ACTN1 and MYBL1-NFIB), which were associated with MYBL1 overexpression. A third AdCC harboured a high-level MYB amplification, which resulted in MYB overexpression at the mRNA and protein levels. RNA-sequencing and whole-genome sequencing revealed no definite alternative driver in the fourth AdCC studied, despite high levels of MYB expression and the activation of pathways similar to those activated in MYB-NFIB-positive AdCCs. In this case, a deletion encompassing the last intron and part of exon 15 of MYB, including the binding site of ERG-1, a transcription factor that may downregulate MYB, and the exon 15 splice site, was detected. In conclusion, we demonstrate that MYBL1 rearrangements and MYB amplification probably constitute alternative genetic drivers of breast AdCCs, functioning through MYBL1 or MYB overexpression. These observations emphasize that breast AdCCs probably constitute a convergent phenotype, whereby activation of MYB and MYBL1 and their downstream targets can be driven by the MYB-NFIB fusion gene, MYBL1 rearrangements, MYB amplification, or other yet to be identified mechanisms.

KW - Adenoid cystic carcinoma

KW - Breast

KW - MYB

KW - MYB-NFIB fusion gene

KW - MYBL1

UR - http://www.scopus.com/inward/record.url?scp=85039164448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039164448&partnerID=8YFLogxK

U2 - 10.1002/path.5006

DO - 10.1002/path.5006

M3 - Article

C2 - 29149504

AN - SCOPUS:85039164448

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

ER -